Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Arcturus cleared to begin phase II study of ARCT-810 for OTC deficiency

July 29, 2021

Phase II study of CETP inhibitor obicetrapib meets primary endpoint

July 29, 2021

Discovery novel GPR119 agonist with excellent blood glucose-lowering effects

July 28, 2021

Dual GCGR and GLP-1 agonists patented by Merck & Co.

July 28, 2021

Inozyme opens enrollment in phase I/II study of INZ-701 for ENPP1 deficiency

July 27, 2021

Denali reports interim data from phase I/II study of DNL-310 in Hunter's syndrome

July 26, 2021

New glucagon-like peptide 1 derivatives identified at Gan & Lee Pharmaceuticals

July 26, 2021

FDA accepts IND application for ATRS-1902 for adrenal crisis rescue

July 23, 2021

Positive data reported from phase Ib study of IMT-002 in T1D with HLA-DQ8 trait

July 22, 2021

NIMIUM and Paraza partner to develop G3PP activators to treat cardiometabolic diseases

July 21, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...